A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Olamkicept (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Leading Biopharm
- 29 Dec 2017 Planned End Date changed from 30 Aug 2020 to 30 Aug 2019.
- 29 Dec 2017 Planned primary completion date changed from 30 Mar 2020 to 30 Jul 2019.
- 29 Dec 2017 Status changed from not yet recruiting to recruiting.